6.1 Acute Cellular Rejection After Liver Transplant

Acute Cellular Rejection After Liver Transplant

Summary of Lecture by Prof. Sanjaya Satapathy, MD, FAASLD

1. Main Clinical Topics Discussed

• Definition, pathophysiology, and epidemiology of acute cellular rejection (ACR) following liver transplantation
• Clinical presentation, laboratory patterns, and diagnostic approach
• Histopathological features of ACR
• Management strategies and treatment protocols
• Differential diagnosis of elevated liver function tests (LFTs) post-transplant
• Common board exam traps and clinical pitfalls

2. Key Learning Points, Guidelines, and Recommendations

Definition & Pathophysiology

• ACR is the most common form of rejection after liver transplantation
• Immune mechanism: T-cell mediated — recipient immune cells recognize donor antigens and attack the allograft
• Generally reversible and treatable when identified early

Timing

• Classic window: 1–3 months post-transplantation
• Can occur earlier with inadequate immunosuppression (non-adherence, under-dosing)
• Can occur later with calcineurin inhibitor (CNI) dose reduction, drug interactions, or minimization of immunosuppression

Clinical Presentation

• Often asymptomatic — discovered on routine laboratory monitoring
• Mild non-specific symptoms possible: low-grade fever, fatigue
• Most common presenting sign: rising liver enzymes (ALT/AST elevation)

Laboratory Pattern

• Classic pattern: hepatocellular injury — elevated ALT and AST
• Pattern may be mixed or cholestatic, particularly later in the course
• Bilirubin elevation typically occurs later in the disease course
• Key pearl: Rising liver enzymes combined with low tacrolimus levels = classic ACR scenario → proceed to liver biopsy

Histopathologic Triad (Classic for Boards)

• Portal inflammation — lymphocytic infiltration of portal tracts
• Bile duct injury — lymphocyte-mediated damage/degeneration of bile duct epithelium
• Endotheliitis — inflammation of venous endothelium involving portal vein branches
• *Note: Detailed knowledge of the Banff scoring system is NOT required for ABIM examination*

Diagnostic Approach (Stepwise)

1. Check tacrolimus trough level

2. Review medication list for drug interactions (CYP3A4 inducers/inhibitors)

3. Obtain Doppler ultrasound to rule out hepatic artery thrombosis (HAT)

4. Evaluate for biliary complications (anastomotic stricture, biliary obstruction)

5. If no vascular or biliary cause identified → liver biopsy for definitive diagnosis

Treatment

• Mild-to-moderate ACR: High-dose IV corticosteroids — typically IV methylprednisolone pulse (~500 mg/day × 3 days)
• Followed by oral steroid taper
• Monitor response via serial LFTs (ALT/AST improvement expected within days)

3. Specific Clinical Data, Statistics, or Study Results Cited

• No specific clinical trials or quantitative study data were cited in this lecture
• Emphasis placed on board-relevant clinical principles and established clinical practice patterns rather than specific research statistics
• Tacrolimus drug interaction example cited: Rifampin (strong CYP3A4 inducer) → accelerated tacrolimus metabolism → reduced tacrolimus levels → increased rejection risk

4. Practical Takeaways for Clinicians

• Always consider timing from transplant when evaluating elevated LFTs — the post-transplant interval is the first diagnostic clue
• Do not empirically start steroids without systematic evaluation; premature immunosuppression can mask alternative diagnoses and increase infection risk
• Check tacrolimus levels first — low levels suggest under-immunosuppression; high levels may indicate CNI toxicity
• Drug interactions are clinically critical: Rifampin, azole antifungals, and macrolide antibiotics significantly alter tacrolimus metabolism via CYP3A4
• Differential diagnosis for elevated post-transplant LFTs must always include: